Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23

Benzinga Newsdesk www.benzinga.com Neutral 54.9%

Neg 0% Neu 54.9% Pos 0%

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.